Primary information |
---|
ID | 13491 |
Uniprot ID | Q90Y12 |
Description | Bradykinin potentiating and C-type natriuretic peptides (BPP-CNP) [Cleaved into- Bradykinin-potentiating peptide Cdt1a; Bradykinin-potentiating peptide Cdt1b; Bradykinin-potentiating peptide Cdt2; Bradykinin inhibitor peptide Cdt3; C-type natriuretic peptide (CNP)] |
Organism | Crotalus durissus terrificus |
Txonomy | Eukaryota; Opisthokonta; Metazoa; Eumetazoa; Bilateria; Deuterostomia; Chordata; Craniata; Vertebrata; Gnathostomata (jawed vertebrates); Teleostomi; Euteleostomi; Sarcopterygii; Dipnotetrapodomorpha; Tetrapoda; Amniota; Sauropsida; Sauria (diapsids); Lepidosauria (lepidosaurs); Squamata (squamates); Bifurcata (split-tongued squamates); Unidentata; Episquamata; Toxicofera; Serpentes (snakes); Colubroidea; Viperidae; Crotalinae (pit vipers); Crotalus; Crotalus durissus (tropical rattlesnake); Cro |
Subcellular Location | Secreted |
Developmental Stage | NA |
Similarity | In the N-terminal section; belongs to the bradykinin-potentiating peptide family. |
Tissue Specificity | Venom gland. |
Post Translational Modification | NA |
Function | Bradykinin-potentiating peptide both inhibits the activity of the angiotensin-converting enzyme (ACE) and enhances the action of bradykinin by inhibiting the peptidases that inactivate it. It acts as an indirect hypotensive agent. Synthetic Cdt1a; Cdt1b and the short hexapeptide Cdt3 are able to potentiate the hypotensive effect mediated by Bk on the blood pressure of anesthetized rats. |
Length | 181 |
Molecular Weight | 18 |
Name | NA |
Sequence | NA |
Sequence map | NA |
PDB ID | NA |
Drugpedia | NA |
Receptor | NA |
Domain | NA |
Pharmaceutical Use | NA
|